STOCK TITAN

Impel Pharmaceuticals Inc - IMPL STOCK NEWS

Welcome to our dedicated news page for Impel Pharmaceuticals (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Impel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Impel Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
Impel Pharmaceuticals Inc

Nasdaq:IMPL

IMPL Rankings

IMPL Stock Data

5.76M
7.99M
0.52%
71.62%
3.56%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Seattle

About IMPL

impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.